New York, NY -- (SBWIRE) -- 09/16/2013 -- StockMarketIntel.com issues a special report on the following stocks: Celsion Corporation (NASDAQ:CLSN), Sequenom, Inc. (NASDAQ:SQNM), Advanced Semiconductor Engineering (ADR) (NYSE:ASX), Peregrine Pharmaceuticals (NASDAQ:PPHM)
Celsion Corporation (NASDAQ:CLSN)’s number of shares traded in the last trading day were 1.21 million, on the other hand, its average trading volume was 2 million shares. In prior session, the stock tumbled -1.64% and closed the trading activity at $1.20. Watching the stock’s previous 5 day trend, the stock showed a bearish move of -11.76%. Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology.
Has CLSN Found The Bottom and Ready To Move Up? Find Out Here
Sequenom, Inc. (NASDAQ:SQNM) opened the most recent session at the price of $2.93. Its previous closing price was recorded at $2.87. SQNM dropped -1.71% and traded within the range of $2.87 - $2.94 in prior trading activity. The 52 week range of the stock remained in between $2.75 - $5.36. Total volume of the stock was 1.47 million shares during last trade, while its average volume remained 2.85 million shares. Sequenom, Inc., a life sciences company, provides genetic analysis solutions in the United States and internationally. It operates through two segments, Molecular Diagnostics and Genetic Analysis.
Has SQNM Found The Bottom And Ready To Gain Momentum? Find Out Here
Advanced Semiconductor Engineering (ADR) (NYSE:ASX) fell -1.74% and finished the trading at $4.52. Yesterday’s price range of ASX was $4.45- $4.57, while the market capitalization of the stock was 6.75 billion. The stock traded with volume of 1.73 million shares in preceding session, as compared to average volume of 457,403 shares. Advanced Semiconductor Engineering, Inc. provides semiconductor packaging and testing services in the United States, Taiwan, Asia, and Europe.
Will ASX Get Buyers Even After The Recent Rally? Find Out Here
Peregrine Pharmaceuticals (NASDAQ:PPHM), in preceding trading session, showed a bearish movement of -1.84% and remained with market capitalization of 207.19 million. The stock gained volume of 1.33 million shares in prior session, while the average volume was 1.01 million shares. The YTD trend of the stock remained positive +8.54%. Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of monoclonal antibodies focused on the treatment and diagnosis of cancer.
Why Should Investors Buy PPHM After the Recent Fall? Just Go Here and Find Out
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.html
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)